Opening Asia for Russia

China to produce more than 1 billion doses of vaccine this year

23.02.2021 99 просмотров

The production capacity of the inactivated COVID-19 vaccine produced by China's state-owned pharmaceutical corporation Sinopharm will exceed one billion doses in 2021, chairman Liu Jingzhen said in a recent interview with China Central Television (CCTV).

Sinopharm's achievements in the fight against COVID-19 have attracted everyone's attention. The company developed coronavirus nucleic acid test kits within 48 hours, successfully prepared plasma for the treatment of critically ill COVID-19 patients, and took only 335 days from development to obtaining conditional marketing approval for an inactivated vaccine.

Vaccine 1.jpg

"We have developed and developed intensively the development and production of chemicals, biopharmaceuticals, Chinese medicines, and achieved world leadership in 10 aspects," said Liu Jingzhen.

To date, the amount of used inactivated Sinopharm's COVID-19 vaccine has reached over 43 million doses worldwide, of which over 34 million doses have been used domestically.

Vaccine 2.jpg

“The production capacity of the first and second phases of our vaccine project, including the capacity of our production base of the Beijing Institute of Biological Products, will reach one billion doses this year, which can provide enough supply to the market,” said Liu Jingzhen.

According to him, the Wuhan Institute of Biological Products is applying for a conditional marketing authorization for an inactivated COVID-19 vaccine. .

Vaccine 4.jpg

"The Wuhan Phase 1 vaccine project can produce more than 100 million doses of COVID-19 vaccine per year, which can be seen as an important addition to the Sinopharm vaccine project," he said.

many cities in China have begun vaccination of residents, and the number of vaccination sites will gradually increase after the holiday We dreams.

Vaccine 3.jpg
Liu Jingzhennoted that currently the recommended vaccination age for emergency use of COVID-19 vaccines is between 18 and 59 years old, but soon it is expected that all people will be older 18 years old will be able to receive the Sinopharm vaccine, and the circle of recipients will expand.

“The oldest recipient of our vaccine is almost 100 years old. The effect of clinical trials in people aged three to 17 years did not actually show much difference from the test result in people aged 18 to 59 years. So I believe people between the ages of three and 17 will be allowed to get vaccinated soon,” he added.

Vaccine 6.jpg

In addition, Sinopharm is also developing a recombinant protein vaccine against COVID-19, which will soon enter clinical trials. trials.

“The effect of a recombinant protein vaccine against COVID-19 could be better. Meanwhile, its mass production will be relatively easy. Because the inactivated vaccine uses an infectious live virus, it must be produced in high biosecurity P3 laboratories, while recombinant protein vaccines do not require such laboratories. Therefore, after a recombinant protein vaccine is successfully developed, its production will quickly double,” explained Liu Jingzhen.

Vaccine 7.jpg

Liu Jingzhen added that people's awareness of health increased after the epidemic, which opened up new opportunities for the development of the pharmaceutical industry. In particular, biologics, innovative medicines, medical devices, and Chinese medicine medicines will be key areas of development in the future.

Новости партнёров